Research Article

Protective Effect of Curcumin against Doxazosin- and Carvedilol-Induced Oxidative Stress in HepG2 Cells

Mariana Yazmin Medina-Pizaño, Marina Nayeli Medina-Rosales, Sandra Luz Martínez-Hernández, Liseth Rubí Aldaba-Muruato, José Roberto Macías-Pérez, Esperanza Sánchez-Alemán, Javier Ventura-Juárez, and Martin Humberto Muñoz-Ortega

1Center for Basic Sciences, Department of Morphology, Autonomous University of Aguascalientes, Aguascalientes, C.P. 20131, Mexico
2Department of Clinical Chemistry, Faculty of Professional Studies Huasteca Zone, Autonomous University of San Luis Potosí, Ciudad Valles, San Luis Potosí 79060, Mexico
3Center of Basic Sciences, Department of Chemistry, Autonomous University of Aguascalientes, 20131 Aguascalientes, Mexico

Correspondence should be addressed to Martin Humberto Muñoz-Ortega; mhmunoz@correo.uaa.mx

Received 25 August 2021; Revised 19 December 2021; Accepted 18 January 2022; Published 11 February 2022

Academic Editor: Consuelo Borrás

Copyright © 2022 Mariana Yazmin Medina-Pizaño et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Doxazosin and carvedilol have been evaluated as an alternative treatment against chronic liver lesions and for their possible role during the regeneration of damage caused by liver fibrosis in a hamster model. However, these drugs have been reported to induce morphological changes in hepatocytes, affecting the recovery of liver parenchyma. The effects of these α/β adrenoblockers on the viability of hepatocytes are unknown. Herein, we demonstrate the protective effect of curcumin against the possible side effects of doxazosin and carvedilol, drugs with proven anti-fibrotic activity. After pretreatment with 1 μM curcumin for 1 h, HepG2 cells were exposed to 0.1–25 μM doxazosin or carvedilol for 24, 48, and 72 h. Cell viability was assessed using the MTT assay and SYTOX green staining. Morphological changes were detected using the hematoxylin and eosin (H&E) staining and scanning electron microscopy (SEM). An expression of apoptotic and oxidative stress markers was analyzed using reverse transcription-quantitative PCR (RT-qPCR). The results indicate that doxazosin decreases cell viability in a time- and dose-dependent manner, whereas carvedilol increases cell proliferation; however, curcumin increases or maintains cell viability. SEM and H&E staining provided evidence that doxazosin and carvedilol induced morphological changes in HepG2 cells, and curcumin protected against these effects, maintaining the morphology in 90% of treated cells. Furthermore, curcumin positively regulated the expression of Nrf2, HO-1, and SOD1 mRNAs in cells treated with 0.1 and 0.5 μM doxazosin. Moreover, the Bcl-2/Bax ratio was higher in cells that were treated with curcumin before doxazosin or carvedilol. The present study demonstrates that curcumin controls doxazosin- and carvedilol-induced cytotoxicity and morphological changes in HepG2 cells possibly by overexpression of Nrf2.

1. Introduction

The antihypertensive doxazosin, an α-1 adrenergic receptor blocker, has been used to treat benign prostatic hyperplasia and in trials of cardiovascular metabolic disorders as a lipid-lowering agent to prevent heart attack [1, 2]. In addition, doxazosin is known to induce apoptosis in prostate cancer cells [2]. Doxazosin has also been reported to induce apoptosis in cultured cardiomyocytes, possibly independently of blocking α-1 adrenergic receptors [1].

The apoptosis of cultured cardiomyocytes occurs dose dependently at concentrations ranging from 0.1 to 50 μmol/L of doxazosin; this result was reported based on quinazoline, which reacts with different cell targets and leads
to cell cycle arrest and, therefore, a decrease in cell proliferation [2]. In hypertensive patients, the serum doxazosin concentration reaches 0.122 and 0.244 μmol/L with doxazosin doses of 8 and 16 mg, respectively [1]. Carvedilol (1-[carboxyl-(4-oxo]-3-[(2-methoxy-phenoxethyl)-amino]-2-propanol) is a nonselective β-adrenergic antagonist with vasodilator properties that shows an antagonist activity against the α-1 receptors. Additionally, carvedilol has been reported to act as a potent antioxidant [3].

A hamster liver cirrhosis model showed that treatment with doxazosin and carvedilol reduced the concentration of collagen fibers in the liver and improved liver parenchymal function with decreased AST and ALT levels. On one hand, the α-1 antagonist doxazosin modifies the typical morphology of hepatocytes and affects the regeneration process of the parenchyma [4]. On the other hand, the β-adrenoceptor blocker carvedilol is considered antifibrotic owing to its antioxidant activity demonstrated in a rat model of liver cirrhosis treated with carbon tetrachloride and an in vitro model of a liver stellar cell line (LX-2) [3, 5].

Curcumin. Curcumin is a bis-α, β-unsaturated β-diketone with antioxidant activity. The orthomethoxy group of curcumin plays an essential role in oxidative stress; it reacts with reactive oxygen species, and hydrogen donation reactions lead to oxidation and contribute to the well-established of reactive oxygen species- (ROS-) scavenging potential in biological systems [6]. Curcumin positively regulates cytoprotective and antioxidant proteins. However, it can induce a prooxidant effect at high doses [7]. One of the primary defense mechanisms against cytotoxicity is the stimulation of factor 2 related to erythroid nuclear factor 2 (Nrf2) and the activation of the antioxidant response element (ARE). Glutamate-cysteine ligase, thioredoxin reductase 1, NAD(P)H-quinone oxidoreductase 1, and heme oxygenase-1 (HO-1) are regulated by binding of Nrf2 to this consensus binding sequence, Nrf2 signaling pathway, and regulation of the expression of genes involved in ROS elimination [8].

In a previous study, the antifibrotic activity of doxazosin and carvedilol was demonstrated in a CCl4-induced liver fibrosis hamster model subjected to curcumin pretreatment; fibrosis was reversed by decreasing collagen I level, hepatocyte morphology remained intact, and the liver function was normal in the model. The antioxidant curcumin is proposed to increase the mRNA expression of Nrf2, whereas liver fibrosis decreases the antioxidant response of Nrf2 and increases the expression of the nuclear factor kappa B (NF-κB) pathway, a proinflammatory signaling pathway [9].

Based on the abovementioned reports, both doxazosin and carvedilol have been used experimentally to reduce liver fibrosis in vivo and were found to reduce collagen deposition and the number of cells with fibrogenic activity [4, 10, 11]. However, there is little information on the interaction of these drugs with hepatocytes. Therefore, in this study, we determined whether the interaction of these drugs with HepG2 cells as a model of liver cells causes cell damage, as well as evaluated the protective effect of curcumin against this damage.

2. Materials and Methods

2.1. Cell Culture. HepG2 cells (donated from the Immunoparasitology Laboratory, Universidad Autónoma de Aguascalientes, Mexico), were grown in DMEM (D5546; Sigma, St. Louis, MO, USA) supplemented with 2% fetal bovine serum (SU-420, Corning, NY, USA), 2% L-glutamine (25-005-CI; Corning, NY, USA), and 1% penicillin/streptomycin (30-001-CI; Corning) at 37°C in a humidified atmosphere containing 5% CO2 and 95% O2, as proposed by ATCC. After incubation, the cells were rinsed with phosphate-buffered saline (PBS, pH 7.4). The cells were incubated with 1 mL of 0.25% trypsin EDTA for 7 min and harvested by trypsinization. The cells were then collected by centrifugation at 2,000 rpm for 5 min. All cells were harvested during the logarithmic phase of growth.

2.2. Treatments of the Cells with Doxazosin, Carvedilol, and Curcumin. Stock solutions of doxazosin (D9815; Sigma) and carvedilol (PHR1265; Sigma) were prepared at a concentration of 50 mM using DMSO as a solvent. Based on this solution, the preset treatments at concentrations of 0.1, 0.3, 0.5, 10, 15, and 25 μM were obtained using complete DMEM as a solvent. A 1 mg/mL stock solution of curcumin (C1386; Sigma) in 1% DMSO was prepared. Subsequently, a dose-response curve was elaborated using successive dilutions of the stock solution (0.01, 0.03, 0.05, 0.07, 0.1, 0.5, 1, 5, 10, and 25 μM/mL) and evaluating the viability of the HepG2 cells using the MTT assay, to apply 1 h before the interaction with doxazosin and carvedilol.

2.3. MTT Assay. HepG2 cells (1 × 10⁴ cells/well) were cultured in 96-well cell culture plates for 24 h prior to treatment and then treated with the concentrations (0.1, 0.3, 0.5, 10, 15, 25 μM/mL) of doxazosin and carvedilol. Curcumin was added to the cells 1 h prior to treatment with doxazosin and carvedilol. After 24 h, the cells were harvested and the MTT assay was performed.
Figure 1: Cytotoxic activities of doxazosin, carvedilol, and curcumin on HepG2 cells. (a) Doxazosin reduces cell viability timeline and dose dependent in the HepG2 cell line. (b) Carvedilol induces proliferation of HepG2 cells at 24 h, while at 48 h, carvedilol is cytotoxic at low concentrations. (c) Curcumin protects HepG2 cells against the induced cytotoxicity for doxazosin. (d) Curcumin pretreatment-maintained viability in HepG2 cells treated with carvedilol. (e) Curcumin hormesis in HepG2 cells, the viability was analyzed by the MTT assay for 24 h and is presented relative to the activity at the start of the experiment in each case. The results are from three independent experiments. Data are mean ± SD; *p < 0.05, **p < 0.0025, ***p < 0.001, and ****p < 0.0001 versus the control.
and 25 μM) of doxazosin and carvedilol for 24, 48, and 72 h. This treatment was carried out with or without curcumin (1 μM), and pretreatment with curcumin was carried out 1 h before exposure to doxazosin and carvedilol. Cell viability was measured using 5 mg/mL thiazolyl blue tetrazolium bromide (MTT) (M2128; Sigma) dissolved in PBS. Briefly, the cell culture medium with the treatment was changed to medium with diluted MTT (1:10, v/v) and incubated for 4 h at 37°C. After removing the incubation medium, formazan crystals were dissolved in 100 μL of acid isopropanol (84 μL of 25% HCl in 25 mL isopropanol). MTT reduction was quantified by measuring the light absorbance at 595 nm with a reference filter of 655 nm using a microplate reader spectrophotometer (Bio-Rad ® Laboratories, Hercules, CA, USA).

2.4. Hematoxylin and Eosin (H&E) Staining. Cells treated with doxazosin and carvedilol, with or without curcumin (1 μM) pretreatment, were plated at 10^5 cells per well on coverslips at the bottom of 24-well plates. After 24 h, the slide inside the plate was withdrawn and washed with 1x PBS; the cells were then fixed with 4% paraformaldehyde for 20 min at room temperature (25°C), washed with 1x PBS, stained with 500 μL hematoxylin (1 min), followed by two washes with distilled water, counterstained with 500 μL eosin for 20 s, followed by two washes with distilled water, and mounted in Mowiol® (Sigma, 81381). The cells were visualized and analyzed at a magnification of 200x using a Axioskop 40/40 FL light microscope (Carl Zeiss AG, Germany) and analyzed using the Image-Pro Plus Software 4.5.1 (Media Cybernetics, Bethesda, MD, USA).

2.5. Scanning Electron Microscopy. HepG2 cells were analyzed by scanning electron microscopy to observe the morphological changes upon treatment with doxazosin and carvedilol, with or without curcumin (1 μM) pretreatment, during the 24 h challenge. A total of 10^5 cells grown on coverslips in 24-well plates were fixed in 2.5% glutaraldehyde for 10 min at 25°C. The samples were washed with distilled water and dehydrated before being placed on a critical point dryer for 30 min (IR Chamber Scope). Then, the mounted of the sample was carried out. Finally, the samples were plated with gold in Denton Vacuum before observing them with a scanning electron microscope (JEOL JSM-5900 Low Vacuum SEM, Japan).

2.6. SYTOX Green Staining. After completing the treatment with doxazosin and carvedilol, with or without curcumin (1 μM) pretreatment, the DMEM was removed, and the HepG2 cells were fixed on the coverslip where they were cultured and washed with 1x PBS, and the positive damage control was placed with 250 μM of 30% hydrogen peroxide for
15 min. The SYTOX® Green staining solution was prepared by diluting the stock solution to 1:30,000 (167 nm) in 1x PBS; 500 μL of the staining solution was used to cover the cells, followed by incubation for 17 min at 37°C in the dark. The cells were then washed with 1x PBS, the coverslips were mounted with a glycerol gel, and the images were analyzed using a fluorescence inverted microscope, Carl Zeiss 398 Axiovert 40CFL microscope (Carl Zeiss AG, Germany), at a magnification of 200x, with a maximum emission of 504–523 nm.

2.7. Acridine Orange (AO) Staining. To prepare the AO staining solution, the stock was prepared by dissolving 1 g of AO in 100 mL of 1x PBS (pH 7.4) that was stored at 4°C away from light. HepG2 cells (10⁵), which were treated with doxazosin and carvedilol, with or without curcumin (1 μM) pretreatment, were stained with 1 μg/mL AO. After incubation for 15 min at 37°C, the stained cells were washed with 1x PBS. The presence of orange marks due to possible cell damage was evaluated using an inverted fluorescence microscope (Carl Zeiss AG, Germany) at a magnification of 200x, with a maximum emission of 490 nm in red and 515 nm in green.

2.8. Oxidative Stress Detection. Cells were incubated with dihydroethidium (DHE, #D11347, Thermo Fisher Scientific) at 5 μM for 15 min (ex. 490, em. 570 nm), harvested with trypsin, and resuspended in 1x PBS. Finally, cells were evaluated by flow cytometry (Muse Cell Analyzer, Millipore Sigma).

2.9. Isolation of Total RNA and Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR). Twenty-four hours after treatment with doxazosin and carvedilol, with or without curcumin (1 μM) pretreatment, the cells (10⁵ per treatment) were processed with the Direct-zol RNAs MiniPrep® kit, following the manufacturer’s protocol. Total RNA was quantified with a Biodrop (Isogen Life Science, Barcelona, España) and stored at −80°C until use. Reverse transcription was performed with 1 μg of total RNA using the RevertAid First-Strand cDNA Synthesis Kit (K1621, Thermo Scientific, Waltham, MA, USA). Subsequently, real-time qPCR was performed using the Maxima SYBR Green/ROX qPCR Master Mix (2x) (K0221, Thermo Scientific, Waltham, MA, USA) on a StepOne apparatus (Applied Biosystems) with the following conditions: 50°C for 2 min, 95°C for 3 min, 40 cycles of 95°C for 45 s, and 60°C for 45 s. The oligonucleotides used are shown in Table 1. Relative expression levels were normalized against 18S rRNA as an internal housekeeping gene, and differences were determined by employing the ΔΔCt relative method.
2.10. Statistical Analysis. Statistical analyses were performed using Microsoft Excel and GraphPad Prism 6. The results are presented as mean ± SD. D’Agostino-Pearson’s normality test, analysis of variance (ANOVA), and Dunnett’s post hoc test were used for multiple comparisons. p values less than 0.05 were considered statistically significant and are indicated by asterisks as follows: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

3. Results

3.1. Cytotoxicity Assessment Using MTT Assay. Growth inhibitory activity was evaluated using the MTT assay. Cell viability was observed following treatment with different doses of doxazosin and carvedilol for 24, 48, and 72 h. The cell viability was reduced following treatment with doxazosin, which induced a time- and dose-dependent cytotoxic effect. After 24 h treatment with 0.5 μM doxazosin, cell viability was lowered to 87.81% ± 3.95%. After 48 h treatment with 0.1 μM doxazosin, cell viability was lowered to 85.81% ± 3.53% (Figure 1(a)).

On the other hand, cells were slightly less sensitive to carvedilol and showed normal viability after 24 h treatment with 0.1, 0.3, and 0.5 μM of carvedilol, without differences compared to the control (viability 96.54% ± 3.62%). However, 10 μM carvedilol increased HepG2 cell proliferation (cell viability 129.0% ± 4.887%). In contrast, 48 h treatment with low concentrations (0.1, 0.3, and 0.5 μM) of carvedilol was found to be cytotoxic (Figure 1(b)).

3.2. Cell Viability of Curcumin Treatment in HepG2 Cells. The MTT assay showed that curcumin at low doses (< 1 μM) did not show cytotoxic activity. However, doses of 10 and 25 μM induced cell death (viability 76.33% ± 1.097% and 24.01% ± 0.72%, respectively). These results confirmed that 1 μM curcumin had no toxic effect on cell viability (98.18% ± 1.39%) and was selected as a standard pretreatment for subsequent experiments involving treatment with doxazosin and carvedilol (Figure 1(e)).

3.3. Curcumin Reduced Cytotoxicity Induced by Doxazosin and Carvedilol. Treatment with 1 μM curcumin for 1 h before exposure to the antagonists reduced cytotoxicity in HepG2 cells. The viability of curcumin-pretreated cells exposed to 25 μM doxazosin and 25 μM carvedilol (higher dose in both treatments) was increased to 98.83% ± 3.28% and 115.9% ± 2.33%, respectively, compared to the control (Figures 1(c) and 1(d)).

3.4. Effects of Doxazosin and Carvedilol on Monolayer of HepG2 Cells. The morphological changes in the monolayer of HepG2 cells after exposure to doxazosin and carvedilol for 24 h were described as a decrease in the interaction between the cells compared to the control. Doxazosin treatment resulted in dose-dependent balonization and general...
damage at the monolayer detached from adjacent hepatocytes (Figure 2). Treatment with 25 μM carvedilol generated aggregates of eosinophilic cells and cell conglomerates (Figure 2). However, after pretreatment with 1 μM curcumin, cell viability and morphology were found to be maintained during interaction with doxazosin (doxazosin+curcumin (D+C)) and carvedilol (carvedilol+curcumin (C+C)). In addition, cell death decreased, the monolayer integrity was maintained due to an increased interaction between the cells, fewer cell aggregates were visualized, and the number of balloonized cells was decreased (Figure 2).

3.5. Ultrastructural Effects of Doxazosin and Carvedilol on HepG2 Cells and Protection of Cell Integrity Generated by Curcumin. HepG2 cells showed proapoptotic time-and dose-dependent changes with treatment of doxazosin and carvedilol. At 24 h posttreatment, several proapoptotic cells (exhibiting cell shrinkage morphology) as well as cells with cytoplasmic contraction, nuclear condensation, and shedding among adjacent cells were observed. Cells exposed to doxazosin and carvedilol doses ≥10 μM presented features such as balloonization or cell rounding, condensation of cytoplasmic organelles, the appearance of irregularities on the cell surface, cell fragmentation, and the appearance of apoptotic bodies (Figure 3). However, when cells were exposed to curcumin (1 μM) before treatment with the α- and β-adrenoblockers, either doxazosin+curcumin (D+C) or carvedilol+curcumin (C+C), the morphology did not show differences between the treated and control cells and presented a normal nucleus, indicating the no onset of apoptosis or necrosis (Figure 3).

3.6. Curcumin Reduced Membrane Permeability in HepG2 Cells Induced by Doxazosin and Carvedilol. SYTOX green staining shows a distinction between dying cells with intact plasma membrane integrity and necrotic cells. The dose-dependent effect of doxazosin and carvedilol was apparent by staining of dead cells with intense green fluorescence resulting from binding of SYTOX green to cellular nucleic acids. The damage caused by 25 μM doxazosin was very similar to that observed in the H2O2 control. However, pretreatment with 1 μM curcumin before applying doxazosin (D+C) or carvedilol (C+C) reduced the numbers of stained cells and necrotic cells, with no difference compared to the control (Figure 4).

3.7. Doxazosin- and Carvedilol-Induced Cell Damage and Curcumin-Generated Protection in HepG2 Cells. The morphological characteristics of the apoptotic cells induced by doxazosin and carvedilol were determined using AO staining. Doxazosin and carvedilol treatment of cells for 24 h induced several morphological changes such as apoptosis-
like cell shrinkage, nuclear fragmentation (red arrow), and formation of apoptotic bodies (blue arrow) compared to the control cells or cells treated with curcumin that showed normal morphology. Curcumin has a protective effect against the possible proapoptotic effects of doxazosin and carvedilol. Therefore, treatment with curcumin decreased the number of apoptotic bodies and increased the number of cells with nuclear condensation. Furthermore, the cells showed a dose-dependent effect with curcumin treatment at different doses, like the control cells (Figure 5).

3.8 Oxidative Stress Induced by Doxazosin and Carvedilol Decreases in Response to Curcumin. Doxazosin induced oxidative stress and possible cell death. HepG2 cells were exposed to hydrogen peroxide (H$_2$O$_2$) for 15 min as a positive control of oxidative stress (Figure 6). Oxidative stress...
was induced by doxazosin and carvedilol before exposure to curcumin and was analyzed at 24 h using DHE. Untreated and pretreated cells with curcumin showed low levels of oxidative stress, while doxazosin and carvedilol (10 μM) induced a significant increase in ROS production compared to 0.1 μM concentration that did not increase the level of ROS (Figure 6). The antioxidant curcumin pretreatment decreased ROS levels induced by doxazosin and carvedilol. Positive cells for ROS increased to 61% in response to doxazosin 10 μM and decreased to 9% when curcumin was applied before the treatment (Figure 6).

3.9. Curcumin Increased the Expression of Bcl-2 and Nrf2 in Cells Treated with Doxazosin and Carvedilol. Statistically significant differences were observed in the fold change of the mRNA expression levels of Bax, Bcl-2, Nrf2, Keap1, SOD, and HO-1 in HepG2 cells treated with doxazosin and carvedilol, with or without curcumin pretreatment, compared with the untreated cells, using RT-qPCR (p < 0.05). In particular, 10 and 25 μM doxazosin upregulated the proapoptotic gene Bax and downregulated the antioxidant gene Bcl-2 expression. Interestingly, the Bcl-2/Bax expression ratio was increased in cells subjected to curcumin pretreatment (Figure 7(a)). These results strongly support apoptotic induction by doxazosin through upregulation of Bax along with the downregulation of Bcl-2 mRNA expression. Carvedilol treatment led to the downregulation of Bcl-2 and upregulation of Bax expression (Figure 7(b)). The graph shows that the Bcl-2/Bax expression ratio is lower than untreated cells. Therefore, curcumin pretreatment regulates the proapoptotic expression of Bax and the Bcl-2/Bax expression ratio is higher than untreated cells.

The mRNA expression of Nrf2 was increased by doxazosin treatment in the presence and absence of curcumin, followed by increase in Keap1 expression, compared to the control group. The most significant increases in the expression of Nrf2 and Keap1 were observed at a concentration of 0.1 μM (Figures 8(a), 8(b), 8(e), and 8(f)). With a concomitant increase in Nrf2 expression in cells treated with doxazosin, an increase in HO-1 and SOD expression was also observed (Figures 8(c) and 8(d)), while in cells treated with doxazosin and curcumin, the expression levels of HO-1 and SOD increased with 0.1 μM doxazosin treatment and subsequently decreased with treatment at higher concentrations of doxazosin (Figures 8(g) and 8(h)). At a dose of 25 μM, carvedilol treatment upregulated the mRNA expression of Nrf2 (Figure 9(a)), decreased Keap1 (Figure 9(b)) and HO-1 (Figure 9(c)) expressions, and increased SOD expression (Figure 9(d)), compared to the control group. Curcumin treatment along with carvedilol has a similar effect to that observed with doxazosin plus curcumin, showing an initial increase in the antioxidant response generated by Nrf2 and subsequent decrease in expression at higher concentrations of carvedilol (Figures 9(e)–9(h)).

4. Discussion

Based on important antecedents of the interaction of doxazosin and carvedilol with the liver parenchyma, several studies have been conducted, wherein these drugs were used to treat liver fibrosis in animal models, and morphological changes and alterations in levels of liver proliferation markers were observed [4, 9–11]. Recently, the morphological changes induced by these drugs in the HepG2 cells have been reported (unpublished data [12]). Based on these results, the present study was developed to analyze the effect of doxazosin or carvedilol on cytotoxicity, morphological changes, mRNA expression of antioxidant response genes, and cell death in HepG2 cells, which was used as a cell model liver. In addition, the present study demonstrates that curcumin acts as an effective protector against cytotoxicity and morphological alterations and regulates the expression of oxidative stress markers in cells treated with doxazosin and carvedilol. Doxazosin showed time-dependent cytotoxicity after 24 h of exposure, even at lower concentrations. However, carvedilol exhibited a proliferation effect in cells that was significantly different at 24, 48, and 72 h.

Doxazosin and carvedilol caused morphological changes in HepG2 cells, and the treated cells were distinguished from untreated cells by their round shape or balloonization. Serna-Salas et al. [4] demonstrated the effect of these drugs in hepatocytes through H&E staining and observed similar morphological changes in the in vivo model. Therefore, the administration of doxazosin and carvedilol in HepG2 cells could cause oxidative stress and apoptosis or cell necrosis. According to H&E staining results, doxazosin induced a decrease in cell interaction and balloonization, and carvedilol induced the formation of eosinophilic aggregates at higher doses, as observed in chronic lesions in in vivo liver fibrosis models [4, 13]. Curcumin maintained the integrity of the monolayer, during the interaction with doxazosin and carvedilol, possibly due to a decrease in cellular damage caused by these drugs. The effect of curcumin on the cell monolayer was also observed in liver samples obtained from an animal model of liver injury treated with doxazosin and curcumin, as a better recovery of the liver parenchyma in animals treated with curcumin was observed [9]. To determine whether treatments with doxazosin and carvedilol generated HepG2 cell membrane permeability, SYTOX green staining was performed, which allows distinguishing living cells from dead cells [14]. Doxazosin caused dose-dependent damage to the plasma membrane of cells, while carvedilol showed fewer positive cells for this assay. However, treatment with curcumin reduced the membrane damage caused by doxazosin and carvedilol at all doses, consistent with the results of SYTOX green staining. Curcumin can exert protective effects by acting as an antioxidant; this activity can be attributed to its structure, bis-α unsaturated-β-diketone. Furthermore, curcumin can modify thiol Keap1 clusters to release Nrf2 that migrates to the nucleus and induces the expression of antioxidant enzymes [15–17]. A study on liver cells treated with cycloheximide describes the morphological characteristics of hepatocytes in a state of apoptosis by means of transmission electron microscopy; the observed features included condensation of the cytoplasm, nuclear pyknosis, cell contraction, and cell fragmentation [18]. Consistent with these reports, in our study, we found similar morphological alterations in HepG2 cells treated with...
Figure 7: RT-qPCR analysis for Bcl-2 mRNA expression, Bax mRNA expression, and the Ratio of Bcl-2/Bax after treatment with doxazosin and carvedilol at 24 h. (a) Doxazosin upregulated the proapoptotic gene Bax, over the antiapoptotic, Bcl-2, with the doses of doxazosin treatment mainly at 10 and 25 μM. Interestingly, the Bcl-2/Bax expression ratio increased with the treatment curcumin. (b) Carvedilol represents the downregulation of Bcl-2 and upregulation of Bax. The graphic shows the Bcl-2/Bax expression ratio with a value lower than 1. Curcumin pretreatment regulates the propoptotic expression of Bax, and the graphic shows the Bcl-2/Bax expression ratio with a value higher than 1. The results are from three independent experiments. Data are mean ± SD; *p < 0.05, **p < 0.0025, ***p < 0.001, and ****p < 0.0001 versus the control.
doxazosin and carvedilol that may correspond to the process of apoptosis. In addition, we observed multiple fluorescent zones in cells treated with doxazosin, suggesting a progressive fragmentation of the cell body, after which the resultant fragments may give rise to apoptotic bodies.

To analyze whether the morphological changes in HepG2 cells treated with doxazosin and carvedilol corresponded to an apoptosis process and the cells were possibly undergoing drug-activated oxidative stress, we evaluated expression of apoptosis and oxidative stress markers, including Bax, Bcl-2, Nrf2, Keap1, HO-1, and SOD. The 18S rRNA gene was used as an internal control for real-time PCR analysis because it constitutes up to 80%–90% of total cellular RNA [19].

The Bcl-2 family of proteins is the central regulator of the cell-intrinsic apoptotic pathway. Bcl-2 binds to
proapoptotic members, such as Bax, preventing pore formation and cytochrome c release. In contrast, an increase in the expression of Bax induces cell death [20, 21]. Therefore, an altered ratio of proapoptotic and antiapoptotic Bcl-2 family members might be important for understanding the sensitizing effect of doxazosin and carvedilol in these cells. Doxazosin has been reported to induce apoptosis in prostate cells and fibroblasts to treat benign prostatic hyperplasia [22]; the structural quinazoline ring of doxazosin may possibly mediate this effect [23].

Furthermore, in this study, the induction of apoptosis by the highest concentrations of doxazosin was possibly activated by oxidative stress. The results demonstrate that the effects of doxazosin and carvedilol on apoptosis induction in HepG2 cells significantly increased in a dose-dependent manner. When HepG2 cells were treated with doxazosin and carvedilol for 24 h, Bax and Bcl-2 mRNA expression was markedly detectable, but the ratio of expression Bcl-2/Bax was low suggesting a proportional increase of Bax over Bcl-2. It is known that Bax and caspase-9 mRNA expression...
is also upregulated by the remaining p53 in cells with oxidative stress damage [24, 25]. Several studies have shown that cytoplasmic p53 is associated with mitochondria-mediated caspas. p53 settles in the mitochondrial membrane after an importation step involving the mortalin–p53 complex. Similar conclusions were drawn from the results of AO staining, where multiple orange-stained areas were observed in the cytoplasm of cells treated with these drugs.

Furthermore, the results showed an increase in HO-1 and SOD activity after treatment with doxazosin and carvedilol, due to damage generated by oxidative stress. However, carvedilol prevented the increase in HO-1 activity, probably due to the antioxidant mode of action of this drug. It has been suggested that carvedilol inhibits lipid peroxidation by scavenging free radicals [26]. In particular, upon cotreatment with doxazosin and curcumin, Nrf2 mRNA was over-expressed, and it was shown that the expression of the effector mRNA HO-1 and SOD also increased, observing a protective effect of curcumin on HepG2 cells during its interaction with doxazosin. Similar studies have demonstrated that the overexpression of Nrf2 and antioxidant enzymes (HO-1 and SOD) by curcumin treatment protects against different events of cellular damage due to oxidative stress, such as in models of cardiac ischemia, glomerulonephritis, and neuronal damage [15, 27, 22]. Therefore, curcumin pretreatment tends to activate the detoxification signaling pathway genes responsible for protection that are under the control of genes called vitagenes. Vitagenes are a set of genes that are responsible for maintaining cellular homeostasis during stress [28]. The transcription factor Nrf2 upon binding to the ARE element in the nucleus encodes phase II proteins and antioxidant enzymes such as HO-1, Hsp70, thioredoxin, and thioredoxin reductase [29].

Curcumin treatment modulates Nrf2 expression and exerts antioxidant effects by upregulating the expression of HO-1 and SOD [27]. In line with these data, our results showed that upon pretreatment with curcumin and subsequent exposure to doxazosin or carvedilol at different doses, the expression of HO-1 and SOD in the cells was regulated. It has been reported that Nrf2 binds to the promoter region of ARE in the nucleus at the 5′-flanking region and promotes the activation of expression of several phase II detoxification and antioxidant genes [29, 30]. The activation of gene expression occurs through the binding of Nrf2 to the ARE region with high affinity. Activation of the Keap1/Nrf2 signaling pathway also leads to the induction of expression of antioxidant enzymes, such as GPx, SOD, glutathione reductase, and GSH, all of which can scavenge xenobiotics [31]. Our gene expression data suggest that curcumin mediates the disruption of Keap1 dimerization and triggers the release of Nrf2 by protecting HepG2 cells through the expression of HO-1 and SOD. However, a decline in the expression of HO-1 and SOD was observed during 24 h treatment with carvedilol and doxazosin after curcumin pretreatment, possibly because curcumin can activate SIRT1 signaling, which reduces mitochondrial damage. SIRT1 reduces the levels of molecules such as SOD, succinate dehydrogenase, cytochrome c oxidase, aldehyde methane dicarboxylic acid, and H$_2$O$_2$ in the mitochondria [30, 31].

5. Conclusions

Curcumin protects HepG2 cells against oxidative stress-induced cell damage by scavenging ROS through activation of antioxidant genes in the cells, thereby reducing cytotoxicity, reversing the morphological changes induced by the α- and β-adrenoblockers, and attenuating secondary effects. Therefore, it could serve as a treatment for the regeneration process of liver parenchyma in the regression of fibrosis with the α-adrenoblocker doxazosin and the β-adrenoblocker carvedilol.

Abbreviations

\begin{itemize}
  \item $\alpha$: Alpha
  \item $\beta$: Beta
  \item μL: Microliter
  \item AO: Acridine orange
  \item CC$_4$: Carbon tetrachloride
  \item CO$_2$: Carbon dioxide
  \item DMSO: Dimethyl sulfoxide
  \item DMEM: Medio Dulbecco’s modified Eagle’s medium-low glucose
  \item H$_2$O$_2$: Hydrogen peroxide
  \item MTT: (3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyltetrazo-

\begin{itemize}
  \item L: Microliter
  \item α: Alpha
  \item β: Beta
  \item CO$_2$: Carbon dioxide
  \item DMEM: Medio Dulbecco’s modified Eagle’s medium-low glucose
  \item H$_2$O$_2$: Hydrogen peroxide
  \item MTT: (3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyltetrazo-

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Additional Points

\textit{Highlights.} (i) Curcumin generates protection against oxidative stress in liver cells treated with two experimental drugs (doxazosin or carvedilol) used to decrease liver fibrosis. (ii) Curcumin controls doxazosin- and carvedilol-induced cytotoxicity and morphological changes in HepG2 cells. (iii) The Bcl-2 relationship on Bax was higher in cells treated with curcumin before doxazosin or carvedilol. (iv) Curcumin protects HepG2 cells against oxidative stress-induced cell damage by scavenging ROS through overexpression of Nrf2.

Consent

Consent was not necessary.

Conflicts of Interest

The authors declare that they have no competing interests.
Authors’ Contributions

MYMP and MNMR developed cytotoxicity techniques, H&E and AO staining, phase contrast microscopy, and electron microscopy during the treatments with α-adrenergoblockers doxazosin and β-adrenergoblocker carvedilol and the analysis and interpretation of the data of cytotoxicity, biochemical measurements, staining, and scanning electron microscopy. JRMP, LRAM, SLMI, JV, and MHHMO contributed to the study conception and design and the writing and revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgments

We acknowledge PhD Eva María Salinas Miralles of Immunoparasitology Laboratory by the donation of the HepG2 cell line, Autonomous University of Aguascalientes; and LAQB Cintya Eguivel-Dueñas and LAQB Mariana Pérez-Villalobos, Department of Chemical, Autonomous University of Aguascalientes, for their excellent technical assistance; to https://www.researchsquare.com, by the preprinting of part of the manuscript (https://www.researchsquare.com/article/rs-289436/v1). The present study was supported by CONACYT (grant 241312, A1-S-21375, and 907029) as part of the master’s program in Toxicology Sciences of the Autonomous University of Aguascalientes (PIBB 19-11n).

References

[1] J. R. González-Juanatey, M. J. Iglesias, C. Alcaide, R. Piñeiro, and F. Lago, "Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of α1-adrenergic blockade," Circulation, vol. 107, no. 1, pp. 127–131, 2003.

[2] A. Forbes, S. Anoopkumar-Dukie, R. Chess-Williams, and C. McDermott, "Relative cytotoxic potencies and cell death mechanisms of α1-adrenoceptor antagonists in prostate cancer cell lines," The Prostate, vol. 76, no. 8, pp. 757–766, 2016.

[3] E. El-Demerdash, S. A. Abdell-Sattar, W. M. El-Bakly, and E. A. Mohamed, "Antifibrotic effects of carvedilol and impact of liver fibrosis on carvedilol pharmacokinetics in a rat model," European Journal of Drug Metabolism and Pharmacokinetics, vol. 42, no. 5, pp. 767–779, 2017.

[4] S. A. Serna-Salas, Y. D. Navarro-González, S. I. Martinez-Hernández et al., "Doxazosin and carvedilol treatment improves hepatic regeneration in a hamster model of cirrhosis," BioMed Research International, vol. 2018, Article ID 4706976, 11 pages, 2018.

[5] L. Ling, L. Li, G. Wang, D. Meng, Z. Li, and C. Zhang, "Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis," Molecular Medicine Reports, vol. 20, no. 5, pp. 1605–1612, 2019.

[6] K. I. Priyadararsi, "The chemistry of curcumin: from extraction to therapeutic agent," Molecules, vol. 19, no. 12, pp. 20091–20112, 2014.

[7] D. Chattopadhyay, A. Somaiah, D. Raghunathan, and K. Thirumurugan, "Dichotomous effect of caffeine, curcumin, and naringenin on genomic DNA of normal and diabetic subjects," Scientifica, vol. 2014, Article ID 649261, 7 pages, 2014.

[8] E. Balogun, M. Hoque, P. Gong et al., "Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element," Biochemical Journal, vol. 371, no. 3, pp. 887–895, 2003.

[9] J. R. Macias-Pérez, B. J. Vázquez-López, M. H. Muñoz-Ortega et al., "Curcumin and α/β-Adrenergic Antagonists Cointreatment Reverse Liver Cirrhosis in Hamsters: Participation of Nrf2 and NF-xb," Journal of Immunology Research, vol. 2019, Article ID 3019794, 12 pages, 2019.

[10] M. H. Muñoz-Ortega, R. W. Llamas-Ramírez, N. I. Romero-Delgadillo et al., "Doxazosin treatment attenuates carbon tetrachloride-induced liver fibrosis in hamsters through a decrease in transforming growth factor β secretion," Gut and Liver, vol. 10, no. 1, pp. 101–108, 2016.

[11] D. Cervantes-García, A. G. Cuellar-Juárez, G. Borrego-Soto et al., "Adenoviral-bone morphogenetic protein-7 and/or doxazosin therapies promote the reversion of fibrosis/cirrhosis in a cirrhotic hamster model," Molecular Medicine Reports, vol. 16, no. 6, pp. 9431–9440, 2017.

[12] M. Y. Medina-Pizaño, M. N. Medina-Rosas, E. Sánchez-Alemán et al., "Curcumin protects Hep G2 cells from the cytotoxic effect of drugs with anti-fibrotic activity, Preprint Research Square, 2021.

[13] E. Geni, T. Mello, and A. Galli, "Pathogenesis of alcoholic liver disease: role of oxidative metabolism," World Journal of Gastroenterology, vol. 20, no. 47, pp. 17756–17772, 2014.

[14] M. Poot, L. L. Gibson, and V. L. Singer, "Detection of apoptosis in live cells by MitoTracker red CMXROS and SYTO dye flow cytometry," Cytometry, vol. 27, no. 4, pp. 358–364, 1997.

[15] S. González-Reyes, S. Guzmán-Beltrán, O. N. Medina-Campos, and J. Pedraza-Chaverri, "Curcumin pretreatment induces Nrf2 and an antioxidant response and prevents hemin-induced toxicity in primary cultures of cerebellar granule neurons of rats," Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 801418, 14 pages, 2013.

[16] M. Pulido-Moran, J. Moreno-Fernandez, C. Ramirez-Tortosa, and M. Ramirez-Tortosa, "Curcumin and health. Molecules," Molecules, vol. 21, no. 3, p. 264, 2016.

[17] T. Esatbeyoglu, P. Huebbe, I. M. Ernst, D. Chin, A. E. Wagner, and G. Rimbach, "Curcumin—from molecule to biological function," Angewandte Chemie, International Edition, vol. 51, no. 22, pp. 5308–5332, 2012.

[18] G. Faa, G. M. Ledda-Columbano, R. Ambu et al., "An electron microscopic study of apoptosis induced by cycloheximide in rat liver," Liver, vol. 14, no. 5, pp. 270–278, 1994.

[19] P. A. Olsvik, K. K. Lie, A. E. O. Jordal, T. O. Nilsen, and I. Hordvik, "Evaluation of potential reference genes in real-time RT-PCR studies of Atlantic salmon," BMC Molecular Biology, vol. 6, no. 1, p. 21, 2005.

[20] S. Haldar, N. Jena, and C. M. Croce, "Inactivation of Bcl-2 by phosphorylation," Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 10, pp. 4507–4511, 1995.

[21] T. Takehara, T. Tatsumi, E. B. Suzuki, L. Rucker, M. Hennighausen, and N. H. Jinushi, "Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses," Gastroenterology, vol. 127, no. 4, pp. 1189–1197, 2004.

[22] N. Kyprianou, J. P. Litvak, A. Borkowski, R. Alexander, and S. C. Jacobs, "Induction of prostate apoptosis by doxazosin in..."
benign prostatic hyperplasia,” The Journal of Urology, vol. 159, no. 6, pp. 1810–1815, 1998.

[23] N. Kyprianou, T. B. Vaughan, and M. C. Michel, “Apoptosis induction by doxazosin and other quinazoline alpha1-adrenoceptor antagonists: a new mechanism for cancer treatment?,” Naunyn-Schmiedeberg’s Archives of Pharmacology, vol. 380, no. 6, pp. 473–477, 2009.

[24] M. H. Naseri, M. Mahdavi, S. H. Davoodi, M. G. Tackallou, M. Goudarzvand, and S. H. Neishabouri, “Up regulation of Bax and down regulation of Bcl2 during 3-NC mediated apoptosis in human cancer cells,” Cancer Cell International, vol. 15, no. 1, pp. 2–9, 2015.

[25] T. Mitupatum, K. Aree, S. Kittisenachai et al., “MRNA expression of Bax, Bcl-2, p 53, Cathepsin B, Caspase-3 and Caspase-9 in the HepG2 cell line following induction by a novel monoclonal Ab Hep88 mAb: cross-talk for paraptosis and apoptosis,” Asian Pacific Journal of Cancer Prevention, vol. 17, no. 2, pp. 703–712, 2016.

[26] G. E. Ronsein, D. B. Guidi, J. C. Benassi et al., Cytoprotective effects of carvedilol against oxygen free radical generation in rat liver, Redox Report Communications in Free Radical Research, 2005.

[27] E. Tapia, V. Soto, K. M. Ortiz-Vega et al., “Curcumin induces Nrf2 nuclear translocation and prevents glomerular hypertension, hyperfiltration, oxidant stress, and the decrease in antioxidant enzymes in 5/6 nephrectomized rats,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 269039, 14 pages, 2012.

[28] V. Calabrrese, C. Cornelius, C. Mancuso et al., “Vitagenes, dietary antioxidants and neuroprotection in neurodegenerative diseases,” Frontiers in Bioscience (scholar edition), vol. 14, no. 3, pp. 76–97, 2009.

[29] K. Itoh, T. Chiba, S. Takahashi et al., “An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements,” Biochemical and Biophysical Research Communications, vol. 236, no. 2, pp. 313–322, 1997.

[30] C. L. Yang, Y. G. Ma, X. Y. Xue, Y. Y. Liu, H. Xie, and G. R. Qiu, “Curcumin induces small cell lung cancer NCI-H446 cell apoptosis via the reactive oxygen species-mediated mitochondrial pathway and not the cell death receptor pathway,” DNA and Cell Biology, vol. 31, no. 2, pp. 139–150, 2012.

[31] M. Ashrafizadeh, Z. Ahmadi, R. Mohammadinejad, T. Farkhondeh, and S. Samarghandian, “Curcumin activates the Nrf2 pathway and induces cellular protection against oxidative injury,” Current Molecular Medicine, vol. 20, no. 2, pp. 116–133, 2020.